Guggenheim Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and raises the price target from $52 to $55.
May 18, 2023 | 6:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on EyePoint Pharmaceuticals and raises the price target from $52 to $55.
The news of Guggenheim maintaining a Buy rating and raising the price target for EyePoint Pharmaceuticals (EYPT) is positive for the stock. This indicates that the analyst has confidence in the company's growth potential and expects the stock price to rise in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100